This FDA submission is a modest positive catalyst for a pre-revenue micro-cap, but the stock's reaction will depend on the market's perception of the probability of FDA acceptance and the Phase 2b trial design. Monitor for any FDA feedback or meeting outcomes in the coming months, as well as the company's cash runway to fund the planned Phase 2b study.
Price Chart
Executive Summary
Phio Pharmaceuticals announced a key development milestone for its lead siRNA candidate PH-762, submitting a meeting request and comprehensive briefing package to the FDA to support a planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma, following the formal completion of the Phase 1b trial. Clinical supplies for the next study are expected in Q1 2027, and the nonclinical toxicology dosing phase has been completed. This is an early-stage regulatory step with no financial data or clinical results disclosed, making it a modestly positive but highly uncertain catalyst for a $12M market cap pre-revenue biotech.
Key Facts
- Phio submitted a meeting request and comprehensive briefing package to the FDA for PH-762 in cutaneous squamous cell carcinoma.
- The submission follows the formal completion of the Phase 1b trial and supports a planned Phase 2b neoadjuvant study.
- Clinical supplies for the next planned study are expected to be available in Q1 2027.
- The dosing phase of the nonclinical toxicology study has been completed.
- PH-762 is an INTASYL siRNA compound that silences the PD-1 gene, targeting skin cancers including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech with $12M market cap.
Risk Factors
- FDA may not accept the proposed Phase 2b study design or may require additional data before allowing the trial to proceed.
- Phio has a $12M market cap and is pre-revenue; the company will likely need additional financing to fund the Phase 2b study, which could cause dilution.
- PH-762 is still in early clinical development with no efficacy data from the Phase 1b disclosed; the risk of clinical failure remains high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (PHIO) — Batch item 1 | 0001437749-26-030236 |
| Exhibit: ex_1015172.htm | 0001437749-26-030236 |
| Document: 0001437749-26-030236-index-headers.html | 0001437749-26-030236 |
| Document: 0001437749-26-030236-index.html | 0001437749-26-030236 |
| Document: 0001437749-26-030236.txt | 0001437749-26-030236 |
| 8-K Filing (PHIO) — Batch item 6 | 0001437749-26-030236 |
| Exhibit: ex_1015172.htm | 0001437749-26-030236 |
| Document: 0001437749-26-030236-index-headers.html | 0001437749-26-030236 |
| Document: 0001437749-26-030236-index.html | 0001437749-26-030236 |
| Document: 0001437749-26-030236.txt | 0001437749-26-030236 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $1.03 $1.01 | ▼ −1.94% | ▼ −2.05% | $1.01 (−1.95%) |
Aug 14, 2026 6w ago | DEFA14A | $1.06 $1.17 | ▲ +10.38% | ▲ +11.57% | $1.01 (−4.73%) |
Apr 8, 2026 25w ago | 8-K | $1.25 $1.27 | ▲ +1.60% | ▼ −1.59% | $1.01 (−19.21%) |
Apr 8, 2026 25w ago | 424B5 | $1.25 $1.27 | ▲ +1.60% | ▼ −1.59% | $1.01 (−19.21%) |
Mar 5, 2026 30w ago | 8-K | $1.16 $1.17 | ▲ +0.86% | ▲ +2.39% | $1.01 (−12.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access